Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 18/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.60 |
| ▸ | VNN1 | O95497 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3709063 | 0.89 | ADORA2A (0.60) | ADORA2AADORA2BADORA1ADORA3VNN1 | |
| SCHEMBL3661435 | 0.88 | ADORA2A (0.63) | ADORA2AADORA2BADORA1ADORA3VNN1 | |
| SCHEMBL3765363 | 0.87 | ADORA2A (0.65) | ADORA2AADORA2BADORA1ADORA3VNN1 | |
| SCHEMBL3708446 | 0.87 | ADORA2A (0.57) | ADORA2AADORA2BADORA1ADORA3VNN1 | |
| SCHEMBL3710910 | 0.86 | ADORA2A (0.61) | ADORA2AADORA2BADORA1ADORA3VNN1 | |
| SCHEMBL3658263 | 0.86 | ADORA2A (0.64) | ADORA2AADORA2BADORA1ADORA3VNN1 | |
| SCHEMBL3651671 | 0.86 | ADORA2A (0.61) | ADORA2AADORA2BADORA1ADORA3VNN1 | |
| SCHEMBL3651011 | 0.86 | ADORA2A (0.64) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL3714414 | 0.84 | ADORA2A (0.61) | ADORA2AADORA2BADORA1ADORA3VNN1 | |
| SCHEMBL3761495 | 0.84 | ADORA2A (0.58) | ADORA2AADORA2BADORA1ADORA3VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305143-A1 | PYRROLOPYRIMIDINE COMPOUNDS | VERNALIS (R & D) LTD. (GB) | 2010-12-02 | — | — | US | disclosed |
| US-20100305143-A1 | PYRROLOPYRIMIDINE COMPOUNDS | VERNALIS (R & D) LTD. (GB) | 2010-12-02 | — | — | US | disclosed |
| US-20100305143-A1 | PYRROLOPYRIMIDINE COMPOUNDS | VERNALIS (R & D) LTD. (GB) | 2010-12-02 | — | — | US | disclosed |
| EP-2203452-A1 | PYRROLOPYRIMIDINE COMPOUNDS | Vernalis (R&D) Ltd. (GB) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009037467-A1 | PYRROLOPYRIMIDINE COMPOUNDS | VERNALIS (R & D) LTD. (GB) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009037467-A1 | PYRROLOPYRIMIDINE COMPOUNDS | VERNALIS (R & D) LTD. (GB) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305143-A1 | PYRROLOPYRIMIDINE COMPOUNDS | ADORA2B, CNR2, CNR1 | ADORA2A 15/4885ADORA2B 1/4885ADORA1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.